Bio-Thera And Intract Partner For Oral mAb Project

Chinese Biosimilars Specialist Licenses Soteria And Phloral Drug Delivery Technologies

 
• By David Wallace
  
Monoclonal antibodies mabs
Bio-Thera will use Intract’s technology to develop novel oral mAbs • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products